Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma by Zhu-Ling Guo et al.
RESEARCH Open Access
Genetically modified "obligate" anaerobic
Salmonella typhimurium as a therapeutic
strategy for neuroblastoma
Zhu-Ling Guo1, Bin Yu2,4, Bo-Tao Ning5, Shing Chan1, Qiu-Bin Lin2, James Chun-Bong Li1, Jian-Dong Huang2,3*
and Godfrey Chi-Fung Chan1*
Abstract
Background: Neuroblastoma currently has poor prognosis, therefore we proposed a new strategy by targeting
neuroblastoma with genetically engineered anaerobic Salmonella (Sal-YB1).
Methods: Nude and nonobese diabetic-severe combined immunodeficiency (NOD-SCID) orthotopic mouse models
were used, and Sal-YB1 was administered via tail vein. The therapeutic effectiveness, bio-safety, and mechanisms were
studied.
Results: No mice died of therapy-related complications. Tumor size reduction was 70 and 30 % in nude and NOD-SCID
mice, respectively. No Salmonella was detected in the urine; 75 % mice had positive stool culture if diaminopimelic
acid was added, but all turned negative subsequently. Tumor tissues had more Sal-YB1 infiltration, necrosis, and
shrinkage in Sal-YB1-treated mice. Significantly higher expression of TLR4, TNF-stimulated gene 6 protein (TSG6), and
cleaved caspase 1, 3, 8, and 9 was found in the tumor masses of the Sal-YB1-treated group with a decrease of
interleukin 1 receptor-associated kinase (IRAK) and nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor alpha (IκBα). There was a high release of TNFα both in human macrophages and mouse tumor tissues with
Sal-YB1 treatment. The antitumor effect of the supernatant derived from macrophages treated with Sal-YB1 could be
reversed with TNFα and pan-caspase inhibitors.
Conclusions: This new approach in targeting neuroblastoma by bio-engineered Salmonella with the assistance of
macrophages indirectly may have a clinical therapeutic impact in the future.
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Background
Neuroblastoma is an aggressive pediatric malignant tumor
with high variability in biological and clinical behaviors
[1–3]. Despite intensive multi-modality therapies, the out-
come of advanced stage neuroblastoma remains extremely
poor. Novel therapeutic approach to improve the survival
of this group of children is urgently needed.
It is known that cancer stem cells remain viable in the
hypoxic tumor core with minimal blood supply. Hence,
this affects the drug delivery and has been considered a
resistant mechanism to conventional chemotherapy for
cancer [4–7]. Attenuated pathogens such as Salmonella
typhimurium and measles virus have been adopted as a
form of biotherapy among the burgeoning anti-cancer
strategies [8–10]. However, many of such “bio-bullets” still
face the challenge of balance between potential side-
effects and anti-cancer effectiveness [11, 12]. Systemat-
ically evaluating their effectiveness and safety prior to
their actual clinical application to cancer patients is
mandatory. To overcome such adversity and also mimic
the actual disease characteristics, we proposed to use a
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genetically engineered anaerobe S. typhimurium strain
YB1 (Sal-YB1) as a form of biotherapy for the intra-adrenal
orthotopic xenograft human neuroblastoma mouse models
using either nude or nonobese diabetic-severe combined
immunodeficiency (NOD-SCID) mice [13].
The genetically modified Sal-YB1 can only proliferate in
hypoxic environment (oxygen <0.5 %) [13]. Otherwise, it
must be supplemented with diaminopimelic acid (DAP)
when it is cultured under aerobic condition [12, 13]. For
bacteria, DAP is an indispensible component in the synthe-
sis of cell wall. In the wild type Salmonella strain, DAP is
normally developed by the essential gene asd. The ex-
pression of asd is modified and regulated by the hypoxia-
conditioned promoter in the Sal-YB1 strain. Compared
with the two more commonly used VNP20009 and SL7207
Salmonella strain, this genetically modified Sal-YB1 exhib-
ited excellent in vivo cytotoxic effect and had low therapy-
related death rate on a human breast cancer model [13].
The orthotopic mouse model has been developed by
implanting neuroblastoma into the fat pad of the mice ad-
renal glands, which is the most common primary site of
neuroblastoma in patients. This xenograft model could
simulate the actual microenvironment of the tumor.
Furthermore, nude mouse together with NOD-SCID
mouse model are relatively robust tools to mimic the
deficient immune states of patients undergoing chemo-
therapy [14, 15]. There are specific immune deficiencies
found in both the nude and NOD-SCID mouse. For ex-
ample, the nude mouse cannot generate mature T lym-
phocytes whereas the NOD-SCID mouse has deficient
T- and B-lymphocytes; abnormal natural killer (NK) cells
and macrophages (MΦ) both in terms of numbers and
function. The neuroblastoma cell line SK-N-LP/luciferase
that we used is transduced with the luciferase gene. The
bioluminescence is closely correlated to the tumor growth
under in vivo imaging system Xenogen 100 (IVIS 100).
In the present study, we chose the new generation Sal-
YB1 as the mono-biotherapy for the orthotopic murine
models using mice with different immunological back-
grounds. Our purpose was to investigate the therapeutic
effectiveness and biosafety on both kinds of mice when
they were treated with virulent bacteria. The possible im-
munological mechanism was also explored to guide our
clinical application of this potential “bio-bullet”—Sal-YB1.
Results
Orthotopic neuroblastoma mouse models with or without
Sal-YB1 treatment
Ten nude mice and ten NOD-SCID mice were implanted
with human neuroblastoma initially. However, before the
Sal-YB1 treatment was started, both groups had one mouse
each which died due to paralysis. The paralysis was subse-
quently due to metastasis of orthotopic adrenal neuroblast-
oma cells to the brain within 2 to 3 weeks. Three-week
post-tumor cells transplantation, the nude (n = 8) and
NOD-SCID (n = 8) mice were divided into two groups.
At week 2 after inoculation with or without Sal-YB1, all
mice survived. Rate of region of interest (ROI) change
was significantly different within either nude or NOD-SCID
mice and also between these two groups (P < 0.05). The
post mortem tumor size increase rate post-YB1 treatment
was reduced to 30 % in nude mice and 70 % in NOD-SCID
mice (Fig. 1). Such reduction was mainly due to tumor ne-
crosis as suggested in the following paragraphs.
Mouse body weight and temperature were recorded
daily. The urine and stool were also collected daily for
2 weeks after Sal-YB1 was administered. Although the
body weight declined in the initial 2 days post-YB1 injec-
tion, the nude and NOD-SCID mice of the treated group
regained body weight from day 3 onwards. Body surface
temperature showed no obvious change during the treat-
ment course. On the first day post-YB1 injection, we could
still observe that the mice turned inactive. Rash could be
transiently found on the skin of nude mice, but it was rela-
tively difficult to observe in NOD-SCID due to the pres-
ence of fur. These febrile reactions might reflect transient
bacteremia-triggering immune reaction. However, they
have no evidence in inducing organ damage as reflected
by the tissues examination when the mice were sacrificed.
Ex vivo Sal-YB1 side effect evaluation on mouse models
Flow cytometry, hematoxylin and eosin (H&E), and immu-
nohistochemistry (IHC) staining were applied to evaluate
the cytotoxic activities and tissue distribution of Sal-YB1.
Sal-YB1-treated tumor tissues showed necrosis, which was
tested by annexin V/PI assay and H&E staining (Fig. 2a, b).
IHC staining revealed that Sal-YB1 formed clusters within
the tumor mass (Fig. 2c) for both nude and NOD-SCID
mice without too much differences in their extent of
necrosis. It is interesting to note that there are more
late apoptotic cells (annexin V+/PI+) for the nude mice but
relatively more early apoptotic cells (annexin V+/PI−) for
the NOD-SCID mice as found in the annexin V/PI assay.
However, the total numbers of apoptotic cells (annexin
V+/PI− plus V+/PI+) were more for the nude mice
group (Fig. 2d). The findings suggested that tumor in
nude mice is more susceptible to Sal-YB1 treatment,
reflecting some other factors relating that the immune
system might play a role in the anti-tumor effect.
Salmonella was not detected in the urine. However, 75 %
of the mice had positive Sal-YB1 in their stool. They all
turned negative within 2 weeks. Particularly, Salmonella
was undetectable in stool colony-forming unit (CFU) test
without DAP supplement suggesting that these residual
Sal-YB1 found in the stool will not be able to survive and
proliferate when they were passed under normoxic environ-
ment. No matter if mice with tumor implantation or not,
both nude and NOD-SCID group did not have Sal-YB1
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detected in the heart, spleen, liver, lung, kidney, brain,
spinal cord, and blood at 2 weeks post-treatment. How-
ever, hepatosplenomegaly was observed in Sal-YB1-treated
mice but there was no evidence of either inflammation or
necrosis as shown by annexin V/PI and H&E stain.
Sal-YB1 therapy mechanism on neuroblastoma
Sal-YB1 could significantly upregulate Toll-like receptor 4
(TLR4) expression in tumor tissues by flow cytometry. Inter-
leukin 1 receptor-associated kinase (IRAK) (P < 0.05) and
nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor alpha (IκBα) (P < 0.001) were downregu-
lated in the xenograft triggered by Sal-YB1 as shown by
Western blotting (Fig. 3). There were high release of TNFα
from both human macrophage and mouse tumor tissues in
the Sal-YB1-treated group as shown by ELISA (P< 0.05).
The expression of TNFα in nude mice and 2-day hypoxia-
cultured macrophages were significantly higher than that of
the NOD-SCID mice (Fig. 4a) and normoxia-cultured mac-
rophages (Fig. 4b), respectively. Besides, the Sal-YB1 could
only be detected in hypoxia-cultured macrophages by CFU
counting. The viability of neuroblastoma was decreased
when co-cultured with 50 % supernatant of the YB1 pre-
treated macrophages (P < 0.01); however, it could be rescued
by TNFα inhibitor (P < 0.01) (Fig. 4c, d). These data sug-
gested that the endotoxin (LPS) from salmonella could acti-
vate the TLR4 and the downstream signalling pathway
leading to the release of TNFα by macrophages and the
TNFα will subsequently induce indirect tumor cell killing in
the cancer microenvironment.
Using the supernatant from Sal-YB1 pre-treated mac-
rophages or Sal-YB1 direct treatment on neuroblastoma
could induce apoptosis as shown by the JC-1 assay (Fig. 5).
This finding implies the involvement of the intrinsic apop-
totic pathway. Sal-YB1-treated mouse tumor tissues showed
high expression of caspase 3 by flow cytometry (Fig. 6a).
Cleaved caspase 1 (p20) (P < 0.05), cleaved caspase 3
(p17, 19) (P < 0.01), cleaved caspase 8 (p18, 43) (P < 0.05),
cleaved caspase 9 (p37, 39) (P < 0.05), and TNF-stimulated
gene 6 protein (TSG6) (P < 0.05) could be significantly
identified in Sal-YB1-treated tumor mass by Western blot-
ting (Fig. 6b–g). Pan-caspase inhibitor could block the
apoptosis of neuroblastoma, which is treated by post-
activated macrophage culture supernatant (P < 0.001)
and Sal-YB1 (P < 0.05) (Fig. 4e, f ). These findings fur-
ther supported that the TNFα by macrophages induced
indirect tumor cell killing in the cancer microenviron-
ment via caspase-dependent apoptotic pathway.
Discussion
In the past decades, the paradigms of cancer treatments
are mainly based on surgical resection, irradiation, chemo-
therapy, immunotherapy, and targeted therapy. There are
also advocates on using alternative approaches including
homeopathic therapy, hyperthermia, or some other strat-
egies but all with doubtful impact [16, 17]. Neuroblastoma
is the most common childhood extracranial solid tumor
Fig. 1 Sal-YB1 could suppress neuroblastoma growth in both nude and NOD-SCID mice. Tumor growth with/without Sal-YB1 treatment was assessed
by a in vivo imaging system and b tumor size measurement. The tumors and kidneys were placed on a 30-mm-diameter dish. c Rate of ROI change
was significantly different within either nude or NOD-SCID mice and also between these two groups (P < 0.05). d The post mortem tumor size increase
rate post-YB1 treatment was reduced to 30 % in nude mice and 70 % in NOD-SCID mice when compared to control (P < 0.05). The error bars showed
means ± SEM for four mice in each group. *P < 0.05 by an unpaired two-tailed t test
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derived from neural crest cells [2, 18]. Although a minor-
ity of cases spontaneously regress, more than half of the
children suffered from metastatic disease at diagnosis, and
they have poor prognosis despite current therapeutic ap-
proaches [19–21].
Recently, novel treatment such as using an attenuated
measles virus to patients with disseminated myeloma raised
the possibility of applying biotherapy with genetically modi-
fied microorganism [8]. Such approach has been attempted,
but its clinical application has been limited by low efficacy
and potential adverse effects. Currently, SL7207 has been
tested as a form of lived bacterial vaccine in pre-clinical
studies [22–24]. Here, we proposed a novel treatment
strategy by using an engineered anaerobe Salmonella
strain Sal-YB1. Such “bio-bullet” has a survival advantage in
a hypoxic environment, which is a common phenomenon
within the cancer core where the cancer stem cells reside.
Similar to most stem cells, cancer stem cells thrive better in
a hypoxic environment. Therefore, Sal-YB1 may overcome
the current limitations of conventional treatment by getting
rid of the cancer cells within the hypoxic microenviron-
ment. Sal-YB1 only replicates under a hypoxic environment
and therefore is unlikely to cause serious infection in the re-
cipient. Furthermore, any potential infection can also be
easily controlled by conventional antibiotics. Compared to
chemotherapy, it has the advantage of having less off-target
organ toxicity. In addition, unlike measles virus therapy, the
issue of immune rejection effect of Salmonella is unlikely
as there is no routine vaccination for Salmonella. As in our
animal model, Sal-YB1 can effectively target at the tumor
mass with minimal side effect on the mice.
How the Sal-YB1 induced cell death of cancer such as
neuroblastoma cells remains unknown. There may be dir-
ect or indirect effects on the cancer cells. To find out the
likely influence of the host immune system on such cyto-
toxicity, we make use of two different types of immune-
deficient mice to find out the possible involvement of the
host immune system. Nude mice (deficient in T cells) and
Fig. 2 Sal-YB1 could induce cell death in neuroblastoma xenografts of both the nude and NOD-SCID mice. Tumors with YB1-treated and -untreated
groups were evaluated by a flow cytometry (FCM), b hematoxylin and eosin (H&E), and c immunohistochemistry (IHC) staining, respectively. Salmonella
could be detected within the tumor mass. Scale bar: 50 μm. d Bar diagrams of Annexin V/PI result with statistical analysis. The error bars showed
means ± SEM for four mice in each group. *P < 0.05 and ***P < 0.001 by an unpaired two-tailed t test
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NOD-SCID mice (deficient in T, B, NK cells, and MΦ)
were used in our orthotopic xenograft neuroblastoma
mouse model [14, 15]. The mice were applied to mimic
the induced immune-deficient state of cancer patients
after chemotherapy. Despite the severe immune-deficient
state of the mice, none of them died of infection. Interest-
ingly, we noted a much higher tumor necrosis rate among
nude mice than NOD-SCID mice, suggesting the contribu-
tion of non-T immune cells in the event. On the first day
post-YB1 injection, we observed that all the mice turned in-
active and four nude mice developed transient skin rash,
suggesting transient bacteremia associated with immune
activation leading to inflammation. All the mice subse-
quently regained their body weight 3 days after Sal-YB1 in-
oculation. As the treatment effect was demonstrated in the
mice, the increased body weight should not be contributed
by the progression in tumor burden especially compared to
the control group. While we know that wild type Salmon-
ella can cause infection, or even a chronic carrier state, in
people with normal immunity, our findings suggested that
the anaerobic Sal-YB1 is safe even if applied to these se-
verely immune-deficient mice. But whether Sal-YB1 may be
rejected by immune-competent mice remains unanswered.
Testing of such an approach on transgenic mice with spon-
taneous neuroblastoma development may help to answer
this question. However, we can adopt this approach as an
adjuvant to chemotherapy. Then, the immune rejection
issue will be resolved because chemotherapy can induce an
iatrogenic immune-deficient state.
Referring to the bio-safety concern of potential Salmon-
ella-induced environmental pollution, the excreta was
screened. There was no Salmonella found in the urine of
the mice. Seventy-five percent of mice showed positive
Sal-YB1 in their stool, but they all turned negative within
2 weeks. The genetically modified Sal-YB1 can only prolif-
erate under hypoxic condition or by supplementing with
DAP under aerobic condition. The usual Sal-YB1 detec-
tion was by using DAP-supplemented plate in normal in-
cubation at 37 °C. Here, we double-checked the stool by
parallel DAP-free CFU test. Unlike detection rate in DAP
+ plate, Sal-YB1 is nearly undetectable in DAP-negative
stool culture. Therefore, the worry of Salmonella causing
environmental pollution remains theoretical.
We further explored the possible mechanism of Sal-
YB1-induced cytotoxicity in vivo (Fig. 7). Increased TLR4
expression may account for the resistance of mice to
Gram-negative bacterial infection, for it elicits stronger
immune response from the host [25, 26]. Tumor necro-
sis factor can enhance the lethal effect of endotoxin in
mice, but there is no difference in TNFα expression in
Fig. 3 Sal-YB1 could upregulate TLR4 expression and downregulate IRAK and IκBα in tumor tissues. a Flow cytometry of TLR4. Dashed line, gray filled
histogram, continuous line represented isotype control, YB1-untreated and -treated mice, respectively. Based on the isotype control, TLR4 expression in
the YB1-treated mice was gated as 50.9 %. b IRAK and IκBα Western blotting. There was a significant difference for IRAK (P < 0.05) and IκBα (P < 0.001)
between the YB1-treated and -untreated groups. The band density of IRAK and IκBα were normalized to β-actin. The error bars showed means ± SEM
for three nude mice in each group. *P < 0.05 and ***P < 0.001 by an unpaired two-tailed t test
Guo et al. Journal of Hematology & Oncology  (2015) 8:99 Page 5 of 12
Fig. 4 (See legend on next page.)
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S. typhimurium-infected TLR4+/− mice [27, 28]. Gram-
positive and -negative bacteria could both activate
MyD88/IRAK/IKK/NFκB signalling pathways [29, 30].
Our data showed that Sal-YB1 could upregulate TLR4
expression in the tumor tissues. The direct cytotoxicity
was observed via the activation of TLR4. The treatment
effect was significantly different between nude and
NOD-SCID mice. It is probably due to the number and
function of B cell, NK and macrophages are relatively
preserved in the nude mice [31, 32]. Our investigation
suggested that the indirect anti-cancer effect of Sal-
monella was due to the activation of macrophages. To
test our hypothesis in vitro, we treated the human mac-
rophages with Sal-YB1 and found that Sal-YB1 had sig-
nificant direct stimulatory effect on macrophages. Then,
we collected the supernatant from the macrophages and co-
cultured it with human neuroblastoma cells. The viability of
neuroblastoma was significantly decreased in the group co-
cultured with the supernatant derived from macrophages
pre-treated with Sal-YB1. Moreover, there was a high release
of TNFα from both human macrophages and mouse tumor
tissues in the Sal-YB1-treated group. TNFα and pan-caspase
inhibitors could both reverse the anti-neuroblastoma effect
induced by macrophages. TNFα release from macrophages
as suggested by our in vitro and in vivo experiments is
likely to be one of the cytotoxic components found in
our animal model. Our results highlighted that the
anti-tumor function of Sal-YB1 therapy was mediated
via TLR signalling pathway and the activation of IRAK
and IκBα are determinant for TNFα release. The TNFα
could further trigger the expression of caspase 1 and 8 [33,
34]. Caspase 1 could induce the mitochondria to release
caspase 9 through the complex multistep process. Both cas-
pase 8 and 9 could activate caspase 3-induced apoptosis
[35–38]. On the contrary, TSG6, the negative feedback loop
during the inflammatory/apoptosis network, could be up-
regulated by LPS and TNFα [39, 40]. These downstream
apoptotic related proteins could all be detected to have en-
hanced expression in our nude mice tumor tissues. Thus,
one of the possible mechanisms of Sal-YB1-induced cyto-
toxic effect on neuroblastoma may be due to the activation
of macrophages by Sal-YB1.
The limitation of the current study is that the status of
immunodeficient mice is not totally similar to the post-
chemotherapy-treated immunosuppressed mice for they
are often having neutropenia as well. Currently, there are
(See figure on previous page.)
Fig. 4 Sal-YB1 could enhance the anti-neuroblastoma effect of macrophages via TNFα. TNFα ELISA assay quantified the Sal-YB1 targeting effect on
both a mouse tumor tissues and b human macrophages. Relatively, the expression of TNFα in nude mice and 2-day hypoxia-cultured macrophages
were significantly higher than in NOD-SCID mice and nomoxia-cultured macrophages, respectively (P< 0.05). The error bars showed means ± SEM for
three mice in (a) and three healthy human donators in (b). *P < 0.05 by an unpaired two-tailed t test. c TNFα and pan-caspase inhibitors could reverse
the anti-neuroblastoma effect by macrophages. The viability of neuroblastoma was evaluated by XTT test. Pan-caspase inhibitor blocked the apoptosis
of neuroblastoma both in Sal-YB1 (P< 0.05) and 50 % supernatant of the Sal-YB1 activated macrophages (P< 0.001)-treated group. Anti-TNFα significantly
rescued neuroblastoma co-cultured with the supernatant from YB1 pre-treated macrophages (P< 0.01). The error bars showed means ± SEM in triplicate
experiments. *P< 0.05, **P< 0.01, and ***P< 0.001 by an unpaired two-tailed t test
Fig. 5 Sal-YB1 could decrease the survival of neuroblastoma via JC-1 assay. JC-1 flow cytometry indicated that the survival of neuroblastoma
(gated in the upper box) decreased after either Sal-YB1 direct treatment or co-culture with Sal-YB1 pre-treated activated macrophages
culture supernatant
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several mouse models with spontaneous neuroblastoma
development such as those with amplified MYCN [41] or
mutated ALK [42]. In future study, we can make use of
such models to simulate the actual clinical setting and test
our approach. Our proposed possible underlying mecha-
nisms can also be revisited and verified.
Conclusions
In conclusion, our approach provides a new paradigm in
targeting cancer cells residing within the hypoxic micro-
environment. Even in mice with severe immune-deficient
backgrounds such as nude or NOD-SCID, the Sal-YB1
could still induce tumor necrosis without causing severe in-
fection. The macrophages recruited by Sal-YB1-directed
therapy may play a significant role in fighting against the
cancer. Even Sal-YB1 is not tumor specific, it helps to con-
trol both primary refractory tumors and metastatic tumors
via direct and indirect pathways. Sal-YB1 can also serve as a
therapeutic vector in carrying drugs to poorly vascularized
hypoxia regions, so it may open up another new frontier in
eradicating cancer in the future.
Methods
Culture of Salmonella strains SL7207 and YB1
S. typhimurium strain YB1 was kindly provided by Prof.
JD Huang. Sal-YB1 was cultivated at 37 °C in Luria-Bertani
(LB) broth (USB, Cleveland, USA) containing 25 μg/mL
chloramphenicol, 50 μg/mL streptomycin (Sigma-Aldrich,
St. Louis, USA), and 50 μg/mL DAP (DACO, Tokyo, Japan).
OD600 was measured to determine the bacterial count. The
final calculation was based on 1 OD unit of bacteria
medium equivalent to 109 bacteria.
Maintenance of human neuroblastoma cell lines and
macrophages
SK-N-LP/luciferase cell line passages 7–10 were cultured in
Dulbecco’s modified Eagle’s medium-high glucose (DMEM-
HG), supplemented with 100 U/mL penicillin, 100 mg/mL
Fig. 6 Sal-YB1 could trigger the caspase-dependent apoptosis signalling pathway. a YB1-treated mouse tumor tissues showed high expression of caspase
3 by flow cytometry. Gray filled histogram and continuous line represented the YB1-untreated and -treated mice, respectively. b–f Cleaved caspase 1, 3, 8,
and 9 and TSG6 could be increased in Sal-YB1-treated tumor tissues by Western blot. gWestern bands. The error bars showed means ± SEM for three nude
mice in each group. *P< 0.05 and ***P< 0.001 by an unpaired two-tailed t test
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streptomycin (Invitrogen, New York, USA), 10 % heat-
inactivated fetal bovine serum (Hyclone, Logan, USA),
and 1000 μg/mL G418 (Roche, Mannheim, Germany).
Macrophages were isolated from healthy human peripheral
blood mononuclear cell and kept in RPMI 1640 (Invitrogen,
New York, USA) medium containing 5 % autologous serum
and 1 % penicillin-streptomycin. The medium was renewed
every other day. Normal incubator was supplied with a hu-
midified atmosphere at 37 °C with 5 % CO2, but the hyp-
oxic chamber was precalibrated with less than 0.5 % O2.
Establishment of orthotopic neuroblastoma mouse model
and treated with Sal-YB1
Four-week-old male nude and NOD-SCID mice were pur-
chased from the Laboratory Animal Unit of the University
of Hong Kong with the approval of the Hong Kong Depart-
ment of Health and Committee on the Use of Live Animals
in Teaching and Research of the University of Hong
Kong (CULATR 2587-11 and 2887-12). Mice were rou-
tinely anesthetized and disinfected for abdominal oper-
ation. With the surgical operation microscope, 2E+05
SK-N-LP/luciferase cells diluted in 50 % Matrigel (BD Bio-
sciences, San Diego, USA) were administered directly to
the fat pad of the mice’s left side adrenal glands. By intra-
peritoneal injection of the luciferin (Invitrogen, New York,
USA), the xenograft condition (no more than 4000 mm3)
was monitored via Xenogen in vivo imaging system bi-
weekly. The ROI was generated automatically, and its value
was normalized under the luminescence interval 12,256 to
2.4512E+07. Three weeks post-tumor cells transplantation,
the mice were divided into two groups according to the
similar tumor ROI value. Sal-YB1 (5E+07 CFU) dissolved
in 100 μL PBS was inoculated via the tail vein of the mice,
whereas the control group was treated with 100 μL PBS
only. The body weight and temperature were recorded and
also the urine and stool were collected daily for 2 weeks.
Then, the mice were sacrificed by an overdose of pentobar-
bital. Tissues of the tumor, heart, lung, spleen, liver, kidney,
brain, and spinal cord were harvested for extro-vivo experi-
ments. The length, width, and height of the tumor were
measured for the calculation of the final xenograft vol-
umes, using formula: 4/3 × π (Length ×Width ×Height)/8.
Histology
Around 1–2 cm3 tissues of the tumor, heart, lung, spleen,
liver, kidney, brain, and spinal cord were resected and im-
mediately immersed in 4 % paraformaldehyde for overnight
fixation. Paraffin-embedded block was sectioned into ap-
proximately 4 μm slices and mounted on polylysine pre-
coated slide. H&E staining was performed to examine the
overall structure and necrosis of the tissues. Salmonella dis-
tribution was detected with rabbit anti-Salmonella (Abcam
Fig. 7 Possible mechanisms of Sal-YB1-induced cytotoxic effects on neuroblastoma. Bio-engineered Salmonella with the assistance of macrophages should
contribute to the neuroblastoma reducing progression. TNFα release from macrophages is likely to be one of the cytotoxic components. Abbreviation:
TLR4 toll-like receptor 4, MyD88 myeloid differentiation primary response gene 88, IRAK interleukin 1 receptor-associated kinase, TAK1 TGF-β-activated kinase
1, IκBα nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha, IKK IκB kinase, NF-kB nuclear factor kappa B, TNFα tumor necrosis
factor alpha, TNFR tumor necrosis factor receptor, TNFAIP6 tumor necrosis factor alpha-induced protein 6, TSG6 TNF-stimulated gene 6 protein,
Casp. caspase
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35156, Cambridge, UK). Bound primary antibody (1:700)
was detected with horseradish peroxidase-conjugated goat
anti-rabbit secondary antibody (1:8000) and then devel-
oped in DAB solution (DACO, Tokyo, Japan). Pictures were
taken under a ×200 light microscope.
CFU test
LB agar plates containing 25 μg/mL chloramphenicol and
50 μg/mL streptomycin were prepared with ±50 μg/mL
DAP supplement. Ten microliters of urine, blood, and bile
were pipettied on DAP+ plate. Stool and tissues of the
tumor, heart, lung, spleen, liver, kidney, brain, and spinal
cord were weighed, homogenized, serially diluted in PBS,
and plated on the previous descried LB agar plates. Sal-
monella colonies were counted after 12–18 h incubation
at 37 °C.
Salmonella targeting neuroblastoma/macrophages in
vitro
SK-N-LP/Luciferase cells were cultured in antibiotic-free
DMEM medium the day before they were co-cultured with
Salmonella at a ratio of 1:500. Salmonella was eliminated
by adding 500 μg/mL gentamycin-supplemented medium
for 20–30 min 2–2.5 h later. Then, the cells were replen-
ished with DMEM containing 100 μg/mL gentamycin
under a normoxia incubator or a precalibrated hypoxic
chamber (O2 < 0.5 %). Similarly, the DMEM was changed
to RPMI1640 for macrophages, and the supernatant of
macrophages was also collected after 2 days. Fifty percent
supernatant of the YB1 pre-treated macrophages was sup-
plemented to the SK-N-LP/luciferase cells for another
2 days.
XTT cell proliferation assay
SK-N-LP/luciferase cells were seeded in a 96-well
plate (around 4000 cells/well). After overnight culture,
SK-N-LP/luciferase cells were pre-treated with DMSO,
TNFα antibody (Sigma-Aldrich, St. Louis, USA), caspase 1
(Biovision, San Diego, USA), and pan-caspase (Calbiochem,
Darmstad, Germany) inhibitors for 2 h, respectively. The
viability of neuroblastoma with Salmonella or macrophages
supernatant treatment was observed by XTT kit (Roche,
Mannheim, Germany) for three continuous days or after
2 days, respectively. The optical density was measured
using a microplate reader at wavelength 450 nm.
JC-1 assay
For the JC-1 (BD, San Diego, USA) analysis, the experi-
ment involved one no-treatment negative control arm and
two experimental treatment arms. The two treatment arms
involved 1 or 2 days treatment, respectively, as illustrated
in the following. The no-treatment control served as a con-
trol for comparison of both 1- and 2-day treatment with
Sal-YB1. The data were analyzed by using FlowJo 8.8.2.
Flow cytometry
Mouse tissues of the tumor, heart, lung, spleen, liver, kid-
ney, brain, and spinal cord were weighed, homogenized,
and filtered with 70 μm cell strainer on ice. Suspension
containing around 5E+04 single cells was prepared to per-
form flow cytometry within 1 h. The apoptosis of neuro-
blastoma triggered by Sal-YB1 was analyzed by annexin
V/PI (BD, San Diego, USA). Annexin V+/PI−, annexin
V+/PI+, and annexin V−/PI+ cells are divided as early
apoptosis group, late apoptosis group, and dead group,
respectively. The TLR4 expression induced by Sal-YB1
was detected by anti-human CD284 (TLR4) PE (HTA
125), using mouse IgG2a K isotype control PE (eBM2a)
(Ebioscience, San Diego, USA). The count of TLR4 posi-
tive expression rate was gated according to the isotype
control. The FITC active caspase 3 apoptosis kits were
purchased from BD Pharmingen. The data were analyzed
by using FlowJo 8.8.2.
ELISA assay
Approximately 1.5 g tumor tissues were homogenized, fil-
tered, and centrifuged at 4 °C. Concentration of TNFα in
the collected supernatant was measured using mouse TNFα
ELISA kit (Ebioscience, San Diego, USA) according to the
manufacturer’s instructions. Macrophages were seeded in a
24-well plate (around 5E+05 cells/well). The supernatant of
macrophages with/without Sal-YB1 treatment was detected
by human TNFα ELISA kit (R&D Systems, Minneapolis,
USA). The optical density was measured using a microplate
reader at wavelength 450 nm with correction at 570 nm.
Cell lysis, SDS-PAGE, and Western blotting
Approximately 5 mg tumor tissues were weighed, homoge-
nized, and lysed directly with radio immune precipitation
assay buffer for 2 h with constant agitation in cold room.
Lysates were clarified by centrifugation for 20 min at
12,000 rpm at 4 °C, and the protein concentrations were
quantificated by protein assay kit (Bio-Rad, Hercules, USA).
SDS-PAGE and Western blotting were performed by
standard techniques. Spectra multicolor prestained pro-
tein ladder (Thermo, New York, USA) was used as the
size standard in gel electrophoresis and Western blot-
ting. Primary rabbit polyclonal antibodies (1:1000) of
IRAK (Millipore 06-872, Bedford, USA), IκBα (Santa
Cruzs c-203, Santa Rosa, USA), and caspase 1, 3, 8, and
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9 (CST, Danvers, USA), and mouse monocolonal anti-
body of TSG6 (R & D Systems 259820, Minneapolis,
USA) in PBS-Tween 20 (Bio-Rad, Hercules, USA) con-
taining 5 % bovine serum albumin (Sigma-Aldrich, St.
Louis, USA) were prepared. Diluted β-actin (1:8000)
(CST 4967, Danvers, USA) was compared as internal con-
trol. Subsequently, 1:4000 secondary anti-rabbit antibody
was used, and immunocomplex was visualized by en-
hanced chemiluminescence (Pierce, Chicago, USA). The
density of the protein bands was calculated by Quantity
One (Bio-Rad, Hercules, USA).
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5
(GraphPad Software, San Diego, USA). Differences between
groups were analyzed by the unpaired, two-tailed Student t
test. All data was presented as the means ± SEM. P value
less than 0.05 was considered as statistically significant.
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